EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants

Ogo Egbuna, Brandon Zimmerman, George Manos, Anne Fortier, Madalina C Chirieac, Leslie A Dakin, David J Friedman, Kate Bramham, Kirk Campbell, Bertrand Knebelmann, Laura Barisoni, Ronald J Falk und 8 weitere

New England Journal of Medicine · 16.03.2023 · 388 (11) · 969-979

DOI: 10.1056/nejmoa2202396 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 16.03.2023. Verfasst von Ogo Egbuna und 19 weiteren Autor:innen. Beteiligte Einrichtung: From Vertex Pharmaceuticals (O.E., B.Z., G.M., A.F., M.C.C., L.A.D., M.E.B., D.A.), and Beth Israel Deaconess Medical Center, Harvard Medical School …. Hauptthemen laut MEDLINE: Apolipoprotein L1, Glomerulosclerosis, Focal Segmental, Proteinuria. Die Arbeit wurde bisher 233-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Vertex Pharmaceuticals, Vertex Pharmaceuticals Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein L1Glomerulosclerosis, Focal SegmentalProteinuriaAnimalsHumansMiceApolipoproteinsBlack or African AmericanCreatinineGain of Function MutationGenetic Predisposition to DiseaseHEK293 Cells

Substanzen

APOL1 protein, humanApolipoprotein L1ApolipoproteinsCreatinine

Autor:innen und Institutionen

  • From Vertex Pharmaceuticals (O.E., B.Z., G.M., A.F., M.C.C., L.A.D., M.E.B., D.A.), and Beth Israel Deaconess Medical Center, Harvard Medical School (D.J.F., M.R.P.) - both in Boston; King's College London, London (K.B.…

Förderung

  • Vertex Pharmaceuticals
  • Vertex Pharmaceuticals Incorporated

Zitieren

APA

Egbuna, O., Zimmerman, B., Manos, G., Fortier, A., Chirieac, M. C., Dakin, L. A., Friedman, D. J., Bramham, K., Campbell, K., Knebelmann, B., Barisoni, L., Falk, R. J., Gipson, D. S., Lipkowitz, M. S., Ojo, A., Bunnage, M. E., Pollak, M. R., Altshuler, D., Chertow, G. M., & VX19-147-101 Study Group (2023). Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. New England Journal of Medicine, 388(11), 969-979. https://doi.org/10.1056/nejmoa2202396

Vancouver

Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, et al. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. New England Journal of Medicine. 2023;388(11):969-979. doi:10.1056/nejmoa2202396

BibTeX
@article{Egbuna2023,
  author = {Egbuna, Ogo and Zimmerman, Brandon and Manos, George and Fortier, Anne and Chirieac, Madalina C and Dakin, Leslie A and Friedman, David J and Bramham, Kate and Campbell, Kirk and Knebelmann, Bertrand and Barisoni, Laura and Falk, Ronald J and Gipson, Debbie S and Lipkowitz, Michael S and Ojo, Akinlolu and Bunnage, Mark E and Pollak, Martin R and Altshuler, David and Chertow, Glenn M and VX19-147-101 Study Group, VX19-147-101 Study Group},
  title = {Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {11},
  pages = {969--979},
  doi = {10.1056/nejmoa2202396}
}
Kostenlos starten →